Shopping Cart
Remove All
Your shopping cart is currently empty
Zotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $129 | In Stock | In Stock | |
| 5 mg | $319 | In Stock | In Stock | |
| 10 mg | $513 | In Stock | In Stock | |
| 25 mg | $987 | In Stock | In Stock | |
| 50 mg | $1,550 | In Stock | In Stock | |
| 100 mg | $2,180 | - | In Stock | |
| 200 mg | $2,950 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $352 | In Stock | In Stock |
| Description | Zotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer. |
| Targets&IC50 | ALK (WT):1.4 nM |
| In vitro | Zotizalkib effectively inhibited wild-type ALK with an IC50 value of 1.4 nM, and also showed inhibitory activity against 26 ALK resistance mutations. Zotizalkib also showed effective inhibition of ALK autophosphorylation in Ba/F3 cells expressing EML4-ALK G1202R, EML4-ALK G1202R/L1196M or EML4-ALK G1202R/L1198F mutations, with an IC50 value of about 3-10 nM. [1] |
| In vivo | Zotizalkib was administered orally at a dose of 2-10 mg/kg twice daily for 2 weeks, with the 2 mg/kg, 5 mg/kg, and 10 mg/kg doses exhibiting 64%, 120%, and 200% dose-dependent tumor growth inhibition, respectively. [1] |
| Synonyms | TPX-0131, TPX0131 |
| Molecular Weight | 447.41 |
| Formula | C21H20F3N5O3 |
| Cas No. | 2648641-36-3 |
| Smiles | C(F)(F)[C@H]1N2C=3C(=CN4C(N3)=C(C=N4)C(=O)NC(C)(C)COC=5C(C2)=CC(F)=CC5)OC1 |
| Relative Density. | 1.56 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (44.7 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.47 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.